title: Brainstem tolerance to conformal radiotherapy of skull base tumors.
abstract: OBJECTIVE
  The aim of this study was to analyze the long-term incidence of brainstem toxicity in patients treated for skull base tumors with high dose conformal radiotherapy.
  
  
  METHODS
  Between 1974 and 1995, 367 patients with chordomas (n = 195) and chondrosarcomas (n = 172) of the base of skull have been treated with combined megavoltage photon and 160 MeV proton radiotherapy. Following 3D treatment planning with delineation of target volumes and critical nontarget structures dose distributions and dose-volume histograms were calculated. Radiotherapy was given an 1.8 Gy or CGE (=Cobalt Gray Equivalent) dose per fraction, with prescribed target doses ranging from 63 CGE to 79.2 CGE (mean = 67.8 CGE). Doses to the brainstem surface were limited to < or = 64 CGE and to the brainstem center to < or = 53 CGE.
  
  
  RESULTS
  Follow-up time ranged from 6 months to 21.4 years (mean = 42.5 months). Brainstem toxicity was observed in 17 of 367 patients attributable to treatment, resulting in death of three patients. Actuarial rates of 5 and 10-year high-grade toxicity-free survival were 94 and 88%, respectively. Increased risk of brainstem toxicity was significantly associated with maximum dose to brainstem, volume of brainstem receiving > or = 50 CGE, > or = 55 CGE, and > or = 60 CGE, number of surgical procedures, and prevalence of diabetes or high blood pressure. Multivariate analysis identified three independent factors as important prognosticators: number of surgical procedures (p < 0.001), volume of the brainstem receiving 60 CGE (p < 0.001), and prevalence of diabetes (p < 0.01).
  
  
  CONCLUSIONS
  Tolerance of brainstem to fractionated radiotherapy appears to be a steep function of tissue volume included in high dose regions rather than the maximum dose of brainstem alone. In addition, presence of predisposing factors as well as extent of surgical manipulation can significantly lower brainstem tolerance in the individual patient.
authors.affiliation: Massachusetts General Hospital, Department of Radiation Oncology, Boston, USA.
authors.forename: J
authors.initials: J
authors.lastname: Debus
authors.forename: E B
authors.initials: EB
authors.lastname: Hug
authors.forename: N J
authors.initials: NJ
authors.lastname: Liebsch
authors.forename: D
authors.initials: D
authors.lastname: O'Farrel
authors.forename: D
authors.initials: D
authors.lastname: Finkelstein
authors.forename: J
authors.initials: J
authors.lastname: Efird
authors.forename: J E
authors.initials: JE
authors.lastname: Munzenrider
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001933:Brain Stem / Q000528:radiation effects*; D002648:Child; D002817:Chordoma / Q000401:mortality / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011879:Radiotherapy Dosage; D019292:Skull Base Neoplasms / Q000401:mortality / Q000532:radiotherapy*